-
Dr. Li Bao: Comprehensive Analysis of Hemophagocytic Lymphohistiocytosis (HLH) from Diagnosis to Treatment
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
-
Dr. Kai Hu: The Application of Immunotherapy in Lymphoma and Myeloma | The 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
-
Dr. Lin Fu: On the Controversies and Advances in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)
On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024…
-
EHA Global Insight丨Dr. Uwe Platzbecker: Breakthrough Advances in Acute Promyelocytic Leukemia Treatment — Key Findings of the APOLLO Study
Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic…
-
Dr. Xiaoyan Ke: Sharing International Advances and Comprehensive Treatment Experience in Lymphoma/Myeloma Diagnosis and Therapy
On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was grandly held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American…
-
Dr. Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: ctDNA Detection for Postoperative Minimal Residual Disease in Liver Cancer
Liver cancer is a highly prevalent and poorly prognosed malignancy, with a postoperative recurrence rate as high as 60%-70%. Postoperative minimal residual disease (MRD) is the main culprit behind cancer recurrence and metastasis, but currently, methods to detect MRD in liver cancer are very limited. At the 2024 American Society of Clinical Oncology (ASCO) Annual…
-
EHA Global Insight丨Dr. Igor Aurer: Updated Guidelines and Insights on HIV-Related Lymphoma Treatment
Patients with AIDS have a significantly higher risk of developing non-Hodgkin lymphoma (NHL) compared to the general population. To promote a deeper understanding and standardized treatment of AIDS-related lymphoma (ARL), a special session titled “ARL: EHA-ESMO Clinical Practice Guidelines” was held at the recent 29th Annual Meeting of the European Hematology Association (EHA 2024). Oncology…
-
Dr. Jihao Zhou: Unveiling the Challenges and Progress in Angioimmunoblastic T-Cell Lymphoma (AITL)
On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of “Precision, Integration, Innovation,” the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American…
Connecting Medical Expertise through Media